Haemonetics Corporation (HAE): Price and Financial Metrics


Haemonetics Corporation (HAE)

Today's Latest Price: $100.46 USD

0.22 (-0.22%)

Updated Apr 9 8:04pm

Add HAE to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 132 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

HAE Stock Summary

  • With a price/earnings ratio of 60.27, Haemonetics Corp P/E ratio is greater than that of about 92.46% of stocks in our set with positive earnings.
  • Price to trailing twelve month operating cash flow for HAE is currently 36.28, higher than 93.58% of US stocks with positive operating cash flow.
  • The volatility of Haemonetics Corp's share price is greater than that of merely 13.57% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Haemonetics Corp, a group of peers worth examining would be NUVA, INGN, ISDR, CARG, and ANGI.
  • Visit HAE's SEC page to see the company's official filings. To visit the company's web site, go to www.haemonetics.com.
HAE Daily Price Range
HAE 52-Week Price Range

HAE Stock Price Chart More Charts


HAE Price/Volume Stats

Current price $100.46 52-week high $140.36
Prev. close $100.68 52-week low $63.41
Day low $98.26 Volume 644,100
Day high $104.42 Avg. volume 577,407
50-day MA $105.09 Dividend yield N/A
200-day MA $118.18 Market Cap 5.05B

Haemonetics Corporation (HAE) Company Bio


Haemonetics designs, manufactures, and markets blood management solutions. The Company serves in three markets, such as manufacturers of plasma-derived pharmaceuticals, blood collectors, and hospitals. The company was founded in 1971 and is based in Braintree, Massachusetts.

HAE Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$100.46$35.96-62%

We started the process of determining a valid price forecast for Haemonetics Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Haemonetics Corp ranked in the 20th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Haemonetics Corp ended up being:

  • The company's debt burden, as measured by earnings divided by interest payments, is 7.13; that's higher than 60.35% of US stocks in the Healthcare sector that have positive free cash flow.
  • 93% of the company's capital comes from equity, which is greater than 83.41% of stocks in our cash flow based forecasting set.
  • The business' balance sheet suggests that 7% of the company's capital is sourced from debt; this is greater than merely 16.55% of the free cash flow producing stocks we're observing.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-63%
1%-63%
2%-62%
3%-62%
4%-62%
5%-61%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as HAE, try CNC, DHR, AZN, PKI, and PPD.


HAE Latest News Stream


Event/TimeNews Detail
Loading, please wait...

HAE Latest Social Stream


Loading social stream, please wait...

View Full HAE Social Stream

HAE Price Returns

1-mo -3.14%
3-mo -13.57%
6-mo -21.84%
1-year 13.35%
3-year 145.62%
5-year 124.44%
YTD -12.57%
2019 14.84%
2018 72.26%
2017 44.48%
2016 24.69%
2015 -13.84%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9334 seconds.